Stock LBPH LONGBOARD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Longboard Pharmaceuticals, Inc. Share Price

Equities

LBPH

US54300N1037

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
19.72 USD +2.44% Intraday chart for Longboard Pharmaceuticals, Inc. +13.07% +227.03%
03-26 Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding CI
03-18 Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) added to S&P Pharmaceuticals Select Industry Index CI

Financials

Sales 2024 * 2.5M 200M Sales 2025 * - Capitalization 767M 61.37B
Net income 2024 * -73M -5.84B Net income 2025 * -104M -8.33B EV / Sales 2024 * 223 x
Net cash position 2024 * 210M 16.81B Net cash position 2025 * 263M 21.05B EV / Sales 2025 * -
P/E ratio 2024 *
-9.31 x
P/E ratio 2025 *
-7.44 x
Employees 50
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.26%
More Fundamentals * Assessed data

Chart Longboard Pharmaceuticals, Inc.

Dynamic Chart

Latest news about Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding CI
Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) added to S&P Pharmaceuticals Select Industry Index CI
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cantor Fitzgerald Raises Price Target on Longboard Pharmaceuticals to $60 From $55, Maintains Overweight Rating MT
B. Riley Raises Price Target on Longboard Pharmaceuticals to $30 From $13, Maintains Buy Rating MT
Longboard Pharmaceuticals Closes $242 Million Public Offering MT
HC Wainwright Adjusts Price Target on Longboard Pharmaceuticals to $60 From $25, Keeps Buy Rating MT
Wedbush Raises Longboard Pharmaceuticals' PT to $32 From $22, Says Offering Removes Near-Term Cash Runway Overhang, Provides Resources to Advance Bexicaserin; Keeps Outperform Rating MT
Longboard Pharmaceuticals Prices $210 Million Stock Offering MT
Longboard Pharmaceuticals Launching Share Offering MT
Sector Update: Health Care Stocks Gain Late Afternoon MT
Longboard Pharmaceuticals Shares Surge After Positive Topline Results for Seizures Treatment MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon MT
Top Midday Gainers MT
Cantor Fitzgerald Raises Price Target on Longboard Pharmaceuticals to $55 From $35, Maintains Overweight Rating MT
More news

Latest transcript on Longboard Pharmaceuticals, Inc.

Logo Longboard Pharmaceuticals, Inc.
Longboard Pharmaceuticals, Inc. - Special Call
More transcripts

Analyst Recommendations on Longboard Pharmaceuticals, Inc.

Cantor Fitzgerald Raises Price Target on Longboard Pharmaceuticals to $60 From $55, Maintains Overweight Rating MT
B. Riley Raises Price Target on Longboard Pharmaceuticals to $30 From $13, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Longboard Pharmaceuticals to $60 From $25, Keeps Buy Rating MT
Wedbush Raises Longboard Pharmaceuticals' PT to $32 From $22, Says Offering Removes Near-Term Cash Runway Overhang, Provides Resources to Advance Bexicaserin; Keeps Outperform Rating MT
Cantor Fitzgerald Raises Price Target on Longboard Pharmaceuticals to $55 From $35, Maintains Overweight Rating MT
More recommendations

Press releases Longboard Pharmaceuticals, Inc.

LONGBOARD PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4) AQ
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15 BU
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) BU
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates BU
LONGBOARD PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4) AQ
More press releases

Quotes and Performance

1 day+2.44%
1 week+13.07%
Current month-8.70%
1 month-6.01%
3 months-15.26%
6 months+262.50%
Current year+227.03%
More quotes

Highs and lows

1 week
17.50
Extreme 17.5
20.72
1 month
16.55
Extreme 16.55
21.90
Current year
16.20
Extreme 16.2
28.15
1 year
3.60
Extreme 3.6
28.15
3 years
2.70
Extreme 2.7
28.15
5 years
2.70
Extreme 2.7
28.15
10 years
2.70
Extreme 2.7
28.15
More quotes

Managers and Directors - Longboard Pharmaceuticals, Inc.

Managers TitleAgeSince
Kevin Lind CEO
 Chief Executive Officer 47 02/01/20
Brandi Roberts DFI
 Director of Finance/CFO 50 31/12/20
Nuggehally Srinivas CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Paul Sekhri CHM
 Chairman 66 30/11/20
Phillip Schneider BRD
 Director/Board Member 68 30/11/20
Vincent Aurentz BRD
 Director/Board Member 56 31/01/20
More insiders

ETFs positioned on Longboard Pharmaceuticals, Inc.

Name Weight AuM 1st Jan change Investor Rating
ADVISORSHARES DORSEY WRIGHT MICRO-CAP ETF - USD ETF AdvisorShares Dorsey Wright Micro-Cap ETF - USD
0.41% 4 M€ -5.15% -
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +2.14% -
More ETFs positioned on Longboard Pharmaceuticals, Inc.

Quotes

Date Price Change Volume
26/04/24 19.72 +2.44% 179,169
25/04/24 19.25 -2.53% 278,620
24/04/24 19.75 -2.57% 304,486
23/04/24 20.27 +8.57% 503,726
22/04/24 18.67 +7.05% 479,700

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes

Company Profile

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. The Company is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). It is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The Company plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. It is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The Company is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.
Sector
Biotechnology & Medical Research
Calendar
06/05/2024 - Q1 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
19.72 USD
Average target price
42.57 USD
Spread / Average Target
+115.88%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LONGBOARD PHARMACEUTICALS, INC. Stock Longboard Pharmaceuticals, Inc.
+227.03% 767M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. LBPH Stock